| 1494 |
National Cancer Institute |
Html |
en |
Urethral Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of urethral cancer. |
| female urethral cancer | 0.376591 |
| major academic centers | 0.28402 |
| lymph node dissection | 0.342065 |
| urinary tract tumors | 0.271423 |
| annual incidence rates | 0.28547 |
| transitional cell carcinoma | 0.949088 |
| PDQ cancer information | 0.378892 |
| distal urethra | 0.410475 |
| commonly used tumor | 0.321815 |
| adjunctive radiation therapy | 0.307204 |
| cancer information summary | 0.365437 |
| definitive radiation | 0.299917 |
| 2-cm tumor-free margin | 0.279143 |
| inguinal node dissection | 0.345806 |
| inguinal nodes | 0.299311 |
| anterior urethral carcinoma | 0.459736 |
| NCI PDQ cancer | 0.276687 |
| ipsilateral node dissection | 0.459423 |
| female urethra | 0.380147 |
| urethral catheter | 0.320637 |
| radiation therapy | 0.634648 |
| urethral cancer | 0.577855 |
| patient selection | 0.261945 |
| tumor margins | 0.303956 |
| single-center case series | 0.440822 |
|
| transitional cell mucosa | 0.339607 |
| ipsilateral palpable adenopathy | 0.268507 |
| urethral neoplasms | 0.326534 |
| 2-cm margin proximal | 0.288589 |
| anterior vaginal wall | 0.284136 |
| node dissection | 0.66141 |
| anterior urethral cancers | 0.391992 |
| prostatic urethra | 0.421315 |
| proximal urethral cancers | 0.428057 |
| Intensity-modulated radiation therapy | 0.317055 |
| large tumors | 0.285311 |
| poor tumor control | 0.307048 |
| low-dose-rate iridium-192 sources | 0.265079 |
| frozen section confirmation | 0.398049 |
| End Results database | 0.287533 |
| inguinal adenopathy | 0.28947 |
| urethral cancers | 0.578678 |
| optimal surgical margin | 0.277613 |
| tumor | 0.331558 |
| stratified squamous epithelium | 0.325971 |
| pendulous urethra | 0.304701 |
| numerous periurethral glands | 0.276798 |
| inferior pubic rami | 0.262509 |
| low level | 0.288208 |
|
CLICK HERE |
| 1625 |
National Cancer Institute |
Html |
en |
Vulvar Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of vulvar cancer. |
| clinical trial | 0.306795 |
| treatment | 0.33468 |
| vulvar cancer | 0.816472 |
| lymph node biopsy | 0.279435 |
| vulvar intraepithelial neoplasia | 0.273676 |
| sentinel lymph node | 0.432305 |
| cancer cells | 0.248189 |
| Recurrent vulvar cancer | 0.242509 |
|
| PDQ cancer information | 0.200769 |
| Radical local excision | 0.22415 |
| cancer clinical trials | 0.214832 |
| lymph nodes | 0.572468 |
| radiation therapy | 0.379761 |
| National Cancer Institute | 0.219981 |
| cancer | 0.970335 |
| clinical trials | 0.629959 |
|
CLICK HERE |
| 1637 |
National Cancer Institute |
Html |
en |
Coenzyme Q10 (PDQ®)–Patient Version |
Coenzyme Q10 is naturally made by the body and can be taken as a pill or injection. Studies have shown it to help protect the heart from damaging side effects of doxorubicin and to stimulate the immune system in cancer patients. Read about the results of clinical trials in cancer patients using coenzyme Q10 in this expert-reviewed summary. |
| cancer treatment | 0.549646 |
| body | 0.488461 |
| PDQ cancer information | 0.604928 |
| Cancer Complementary | 0.504149 |
| clinical trials | 0.78289 |
| CoQ10 supplements | 0.61864 |
| health care providers | 0.511973 |
| mg CoQ10 | 0.629362 |
| cancer information summary | 0.559761 |
| alternative cancer therapies | 0.503732 |
| clinical trial | 0.520374 |
| CAM cancer research | 0.490752 |
| free radicals | 0.529211 |
| therapies | 0.527068 |
| conventional cancer therapies | 0.505246 |
| breast cancer patients | 0.577878 |
| patients | 0.653188 |
| cancer patients | 0.613167 |
| adjuvant therapy | 0.48477 |
| CoQ10 therapy | 0.668716 |
| NCI PDQ cancer | 0.520611 |
| cancer information database | 0.499763 |
| CoQ10 analogs | 0.637275 |
| Therapies Editorial Board | 0.506627 |
|
| cancer information | 0.615008 |
| treatment | 0.639358 |
| cancer prevention | 0.483763 |
| Complementary Therapies Editorial | 0.521183 |
| CoQ10 | 0.914047 |
| Drug Administration | 0.508672 |
| Cancer Information Specialist | 0.495609 |
| cancer cells | 0.510132 |
| Cancer Information Service | 0.558797 |
| treatment clinical trials | 0.486207 |
| National Cancer Institute | 0.655789 |
| studies | 0.570221 |
| alternative medicine | 0.536733 |
| health care | 0.547179 |
| scientific journals | 0.497807 |
| Federal Trade Commission | 0.485869 |
| new treatment | 0.531574 |
| Cancer Care page | 0.483491 |
| breast cancer | 0.62622 |
| animal studies | 0.506664 |
| cancer clinical trials | 0.505899 |
| alternative therapies | 0.521758 |
| cancer information summaries | 0.500194 |
| cancer | 0.924813 |
|
CLICK HERE |
| 1901 |
National Cancer Institute |
Html |
es |
Tratamiento del glioma de tronco encefálico infantil (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del glioma de tronco encefálico infantil. |
| siguientes procedimientos | 0.461896 |
| IRM periódicas | 0.425856 |
| posibles factores | 0.428641 |
| efectos secundarios meses | 0.538429 |
| encéfalo benignos | 0.484108 |
| pontino intrÃnseco difuso | 0.901206 |
| efectos tardÃos | 0.636065 |
| PDQ Efectos tardÃos | 0.495055 |
| National Cancer Institute | 0.428512 |
| sustancia llamada gadolinio | 0.454314 |
| siguientes riesgos | 0.420658 |
| llamada neurofibromatosis tipo | 0.456821 |
| Instituto Nacional | 0.447041 |
| cinasa braf | 0.631095 |
| presente sumario | 0.527425 |
| PDQ Tratamiento | 0.518077 |
|
| determinados cambios | 0.420201 |
| neurofibromatosis tipo | 0.564203 |
| nuevos tipos | 0.430533 |
| sistema nervioso central | 0.564289 |
| Physician Data Query | 0.500648 |
| proteÃna braf | 0.427497 |
| Aboutâ„¢ Brain Tumors | 0.435067 |
| tumor dipg | 0.504754 |
| siguientes enlaces | 0.422666 |
| encefálico infantil recién | 0.732248 |
| panel derecho | 0.429689 |
| cuidado paliativo | 0.460842 |
| siguientes sumarios | 0.465406 |
| largo tiempo | 0.418821 |
| siguientes trastornos | 0.430211 |
|
CLICK HERE |
| 2027 |
National Cancer Institute |
Html |
es |
Prevención del cáncer colorrectal (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer colorrectal y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| Problemas renales | 0.523957 |
| siguientes factores | 0.953317 |
| voluntarios sanos | 0.523051 |
| Physician Data Query | 0.604817 |
| siguientes afecciones | 0.551171 |
| Estados Unidos | 0.609005 |
| posibles daños | 0.574254 |
| cuerpo).ampliar anatomÃa | 0.537676 |
| suficiente ejercicio | 0.534096 |
| prevención revisa | 0.526315 |
|
| menor riesgo | 0.62051 |
| PDQ Prevención | 0.545917 |
| Antecedentes familiares | 0.532247 |
| National Cancer Institute | 0.526671 |
| tumores benignos | 0.586261 |
| siguientes riesgos | 0.524072 |
| siguientes sumarios | 0.58101 |
| alto contenido | 0.561192 |
| Instituto Nacional | 0.54913 |
|
CLICK HERE |
| 3434 |
National Cancer Institute |
Html |
es |
Té y prevención de cáncer |
Hoja informativa que resume los resultados de estudios realizados sobre el té y la prevención del cáncer. Incluye información sobre los ingredientes del té y las consideraciones de seguridad sobre el consumo de esta bebida. |
| tea polyphenol levels | 0.306381 |
| Gynecological Cancer | 0.306129 |
| Zhang M | 0.301852 |
| té oolong | 0.345261 |
| lung cancer | 0.322075 |
| green tea extract | 0.319452 |
| case-control study | 0.308604 |
| British Journal | 0.30281 |
| Breast Cancer Research | 0.324861 |
| Human Nutrition | 0.301844 |
| verde activa enzimas | 0.302661 |
| Singapore Chinese Health | 0.30349 |
| tea polyphenol | 0.33584 |
| black tea consumption | 0.317861 |
| Inoue M | 0.303594 |
| green tea rapidly | 0.307366 |
| nested case-control study | 0.302496 |
| PubMed Abstract | 0.999235 |
| tea consumption | 0.35794 |
| Women’s Health Study | 0.302821 |
| green tea consumption | 0.326657 |
| International Journal | 0.309091 |
| Yang CS | 0.303196 |
| cohort study | 0.312904 |
| Chinese Health Study | 0.305698 |
|
| Hakim IA | 0.303206 |
| Drinking green | 0.302093 |
| té verdeConcentración | 0.313111 |
| Health Study | 0.306628 |
| dietary intake | 0.301921 |
| Ohsaki study | 0.302059 |
| Cancer Research | 0.340725 |
| Iwasaki M | 0.30184 |
| Shanghai Cohort Study | 0.302687 |
| prospective cohort study | 0.306347 |
| subsequent risk | 0.303163 |
| Clinical Nutrition | 0.305674 |
| breast cancer | 0.401322 |
| modestly reduces breast | 0.302193 |
| tea consumption with | 0.307242 |
| extract supplement | 0.301849 |
| Cancer Institute | 0.306085 |
| controlled study | 0.301969 |
| Clinical Cancer Research | 0.312026 |
| prospective study | 0.303895 |
| green tea polyphenols | 0.325122 |
| tea catechins after | 0.306288 |
| Netherlands Cohort Study | 0.306092 |
| té verde—500 mg | 0.313535 |
|
CLICK HERE |
| 3515 |
National Cancer Institute |
Html |
en |
Types of Clinical Trials |
Information about the several types of cancer clinical trials, including treatment trials, prevention trials, screening trials, supportive and palliative care trials. Each type of trial is designed to answer different research questions. |
| agent studies | 0.634708 |
| large number | 0.487416 |
| treatment studies | 0.534627 |
| unnecessary follow-up tests | 0.564207 |
| standard treatments | 0.500667 |
| palliative care trials | 0.620026 |
| nutrition problems | 0.486132 |
| approach prevent cancer | 0.592087 |
| specific changes | 0.499234 |
| researchers | 0.486118 |
| cancer patients | 0.507417 |
| treatment trials | 0.63562 |
| Cancer prevention trials | 0.614093 |
| healthy people | 0.501177 |
| cancer screening trials | 0.613302 |
| chemoprevention studies | 0.50869 |
| health problems | 0.485883 |
| high risk | 0.560244 |
| radiation therapy | 0.500589 |
| new ways | 0.649746 |
| safe dose | 0.499447 |
| life | 0.456389 |
| answers questions | 0.498733 |
| action studies | 0.564584 |
| dietary supplements | 0.491505 |
|
| studies | 0.663766 |
| newer treatment trials | 0.614927 |
| certain medicines | 0.490022 |
| different research questions | 0.599262 |
| new treatment | 0.895243 |
| sleep disorders | 0.486249 |
| disease | 0.456977 |
| effective screening test | 0.579302 |
| certain type | 0.487292 |
| support groups | 0.492526 |
| people | 0.64215 |
| better quality | 0.492262 |
| genetic changes | 0.499368 |
| new treatment help | 0.724782 |
| tumors | 0.439813 |
| cancer clinical trials | 0.74573 |
| new places | 0.514069 |
| trials | 0.781895 |
| treatment help people | 0.60481 |
| cancer risk | 0.517947 |
| cancer | 0.948957 |
| prevention trials | 0.744319 |
| new cancer | 0.533494 |
| test new treatments | 0.617153 |
|
CLICK HERE |
| 3650 |
National Cancer Institute |
Html |
en |
CRISPR: Genome Editing Comes of Age |
A research article about a technique for gene editing known as CRISPR-Cas9. The technique has made it much easier and faster for cancer researchers to study mutations and test new therapeutic targets. |
| next-generation DNA sequencing | 0.3795 |
| new targets | 0.314335 |
| activator-like effector nucleases | 0.397418 |
| potentially druggable genes | 0.453893 |
| future combination therapy | 0.360962 |
| cancer therapy | 0.352224 |
| unique gene | 0.31507 |
| cancer growth | 0.426678 |
| abnormal regulatory networks | 0.387625 |
| cancer cell line | 0.572636 |
| short palindromic repeats | 0.389333 |
| genome editing | 0.387426 |
| new therapeutic targets | 0.398394 |
| genes | 0.545435 |
| cell division | 0.314215 |
| Cancer phenotypes | 0.335586 |
| human cell | 0.318044 |
| target genes | 0.365123 |
| lymphoma cells | 0.394771 |
| cancer drug targets | 0.463263 |
| drug resistant tumors | 0.385077 |
| David Baltimore | 0.313639 |
| Ji Luo | 0.374003 |
| drug resistance | 0.449373 |
|
| DNA sequencing | 0.398873 |
| potential combination therapies | 0.357658 |
| possible therapeutic approaches | 0.357025 |
| gene targets | 0.319574 |
| gene expression—it | 0.322364 |
| drug resistance question | 0.384228 |
| CRISPR libraries | 0.319128 |
| cancer cells | 0.810099 |
| cancer cell lines | 0.446525 |
| Dr. Luo | 0.937997 |
| Dr. Staudt | 0.543567 |
| CRISPR method | 0.325677 |
| CRISPR technology | 0.334008 |
| Hannover Medical School | 0.387381 |
| Cancer Research | 0.352397 |
| normal cells | 0.431696 |
| cancer researchers | 0.367853 |
| CRISPR | 0.510355 |
| cell death | 0.314175 |
| transformative technology | 0.318261 |
| technology | 0.365907 |
| Cancer Genome Atlas | 0.450206 |
| gene editing | 0.330972 |
| genetic changes | 0.316809 |
|
CLICK HERE |
| 4383 |
National Cancer Institute |
Html |
en |
Anyone Can Get Skin Cancer |
No matter if your skin is light, dark, or somewhere in between, everyone is at risk for skin cancer. Learn what skin cancer looks like, how to find it early, and how to lower the chance of skin cancer. |
| skin cancer | 0.964567 |
| UV rays | 0.456636 |
| dark band | 0.53853 |
| new mole | 0.452556 |
| dark patch | 0.449539 |
| body | 0.421991 |
| waxy bump | 0.459872 |
| Wear sunglasses | 0.448376 |
| ) bump. | 0.459875 |
| talk | 0.420942 |
| common sign | 0.451092 |
| skin light | 0.47582 |
| different types | 0.451536 |
| jagged scar | 0.458002 |
| exposure | 0.417645 |
| medical conditions | 0.448166 |
| sore | 0.426359 |
| UVB rays | 0.455332 |
| broad spectrum | 0.449203 |
| women | 0.411421 |
| UVA | 0.425118 |
| sunscreen | 0.411184 |
| high level | 0.447722 |
| dark skin | 0.502452 |
| changes | 0.445228 |
|
| skin conditions | 0.464403 |
| cancer cells | 0.45646 |
| cell skin cancer | 0.522134 |
| firm red lump | 0.495754 |
| sun | 0.50802 |
| skin tone | 0.480812 |
| eyes | 0.41674 |
| old growth | 0.501248 |
| different color | 0.450303 |
| men | 0.411424 |
| certain medicines | 0.448412 |
| advanced skin cancers | 0.508812 |
| younger children | 0.460432 |
| change | 0.452939 |
| long sleeves | 0.44884 |
| No. | 0.411646 |
| skin ulcers | 0.466159 |
| people | 0.446457 |
| doctor | 0.48532 |
| sunlight | 0.422273 |
| cause damage | 0.452334 |
| new growth | 0.497988 |
| risk | 0.471314 |
| low level | 0.448421 |
|
CLICK HERE |
| 15481 |
National Cancer Institute |
Html |
en |
Non-NIH Funded Investigators Submitting Data |
null |
| large storage amounts | 0.821627 |
| Institutional Certification | 0.889959 |
| documents | 0.389667 |
| hughessk@mail.nih.gov. | 0.612992 |
| additional information/clarification | 0.581935 |
| Institutional Certification forms | 0.830868 |
| accession number | 0.58702 |
| scientific community | 0.570468 |
| Non-NIH funded investigators | 0.91136 |
| completeness | 0.389773 |
| DSPs | 0.387872 |
| data submission process | 0.811324 |
| GPA analyst registers | 0.892324 |
| expectations | 0.444558 |
| genomic data | 0.66091 |
| value | 0.344731 |
|
| DCB | 0.394534 |
| data submission formats | 0.897528 |
| NCI subcommittee | 0.653863 |
| dbGaP submission | 0.557126 |
| Basic Study Information | 0.821294 |
| Shannon Hughes | 0.637978 |
| steps | 0.351008 |
| Studies | 0.345806 |
| extramural GPAs | 0.729046 |
| GDC staff | 0.659949 |
| storage fee | 0.567724 |
| plans | 0.351639 |
| data submission | 0.961251 |
| GPA analyst | 0.950832 |
| consideration | 0.365649 |
| Jennifer Strasburger | 0.670922 |
|
CLICK HERE |